Alpha-synuclein in Lewy body disease and Alzheimer's disease.
about
LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stressInteractions between fatty acids and alpha-synucleinMultiple system atrophy: a clinical and neuropathological perspectiveThree dimensions of the amyloid hypothesis: time, space and 'wingmen'Role of α- and β-Synucleins in the Axonal Pathology of Parkinson's Disease and Related SynucleinopathiesThe Parkinson Disease gene SNCA: Evolutionary and structural insights with pathological implicationEvaluation of alpha-synuclein immunohistochemical methods used by invited expertsNext-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.Differentiation of progressive supranuclear palsy: clinical, imaging and laboratory tools.The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease.Differentiating Alzheimer disease-associated aggregates with small molecules.Fluorescence quantum yield of thioflavin T in rigid isotropic solution and incorporated into the amyloid fibrils.Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models.Diagnosis of human prion diseasealpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins.Mutant alpha-synuclein exacerbates age-related decrease of neurogenesis.Cross dimerization of amyloid-β and αsynuclein proteins in aqueous environment: a molecular dynamics simulations study.Beta-synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation: cross-talk with alpha-synuclein and implication for Parkinson's disease.Gene expression profiling combined with bioinformatics analysis identify biomarkers for Parkinson disease.TOM40 mediates mitochondrial dysfunction induced by α-synuclein accumulation in Parkinson's disease.Autophagy in dementias.Neuroinflammation in Parkinson's Disease and Related Disorders: A Lesson from Genetically Manipulated Mouse Models of α-Synucleinopathies.Common structural features of toxic intermediates from α-synuclein and GroES fibrillogenesis detected using cryogenic coherent X-ray diffraction imaging.Possible alterations in β-Synuclein, the non-amyloidogenic homologue of α-Synuclein, during progression of sporadic α-synucleinopathiesBent out of shape: α-Synuclein misfolding and the convergence of pathogenic pathways in Parkinson's disease.Rapid eye movement (REM) sleep behaviour disorder; an easily missed diagnosis, a readily treatable condition.Alpha-synuclein alters Notch-1 expression and neurogenesis in mouse embryonic stem cells and in the hippocampus of transgenic mice.Novel antibodies to phosphorylated α-synuclein serine 129 and NFL serine 473 demonstrate the close molecular homology of these epitopesProtective role of endogenous gangliosides for lysosomal pathology in a cellular model of synucleinopathiesOpposing actions of environmental enrichment and Alzheimer's disease on the expression of hippocampal microRNAs in mouse modelsSporadic Alzheimer's disease begins as episodes of brain ischemia and ischemically dysregulated Alzheimer's disease genes.Role of synucleins in Alzheimer's disease.Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy.Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease.α-Synuclein and DJ-1 as potential biological fluid biomarkers for Parkinson's Disease.Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond.Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential.Mitochondrial dysfunction in psychiatric and neurological diseases: cause(s), consequence(s), and implications of antioxidant therapy.The possible involvement of mitochondrial dysfunctions in Lewy body dementia: a systematic review.Enhanced lysosomal pathology caused by beta-synuclein mutants linked to dementia with Lewy bodies.
P2860
Q24294466-A0289F89-D7F0-44EF-A334-150112C17A48Q24336967-1F14C80C-E7CC-4AA2-8D12-C97648BC1AB6Q26829838-B43EE517-2BAC-4DF5-9CB5-1112D4A1EE88Q28082768-96570237-BB7E-4661-BE8F-B1BB5D35EAA3Q28083418-5BF7304F-8C60-45D9-A1DB-05645C9FF6A6Q28604244-7F077996-A539-4301-9637-5200457E81C6Q30488694-F35E1E7F-12E0-4100-8839-BB73FAF67077Q30578913-1FA6CB60-9E25-4B71-8E22-C958C9122141Q30588544-A001C62A-0AF9-4AB5-A31A-04AA2B4F1AF9Q31807516-D9DB55E7-1E5D-4B11-8C33-D4DB5B7213EAQ33296123-59BAE859-74BD-4EE9-BC6C-86FDE7796D6BQ33737447-C67436C6-6F2D-4556-A75F-6AE64E909636Q33865366-D01086AF-BD57-4406-B3EE-FD264F2F2645Q33927533-B17244EE-B251-4954-843C-D12FF3D821DEQ33929879-EA04B988-8DE2-44F4-930D-FFE77132C8DBQ33958241-68928300-78B6-4F07-B10B-898888009796Q34165988-C278CDF2-CDC0-4936-8B89-F35DA94E47ABQ34214842-8B4B1872-ADC3-40A6-9D5B-1DA2EB822E20Q34533646-23C4AC96-1F0D-4614-AC84-F4BB2DD493B4Q34692945-EE3B48B6-8288-41AA-A439-9EAB8336071EQ35624697-107CEC0C-8367-403E-B0B3-813B99E1EBAFQ35884977-61C63D82-BB7B-4C3A-BA69-E96A6F457EB4Q36107686-7EC5CF29-41B0-4CF6-B5AE-DBDA45BD4A45Q36321837-0E2A47DD-B0CC-4FBE-808F-7847CCF14920Q36373170-B71C9AB9-C4B8-4173-8AE3-6CA609705A74Q36777134-4750E907-F9A4-4C1C-93DF-9D6F0DEE3489Q37152191-D76B2F1E-6192-4A59-A405-1105B66997D7Q37160673-D6132D0A-D94D-4700-AE60-E4627F532B4AQ37164257-87581A5B-5D33-41A0-A228-DECDBC202DCFQ37201369-B36BF6EE-040B-44E2-9D05-2D02D763E173Q37301029-C9737DF7-F3B8-4B31-85D0-378E87B0F07AQ37306581-36AD34D3-7167-4125-B3AE-5B9B8B7E5D60Q37586721-F416CA35-B7E4-4B02-BF8C-E7349981EB2FQ37791469-0D1AAF69-8262-4AF4-8E55-1384991FBAD9Q37820120-8FFACB99-43C3-47DA-8958-57EF8CD46D09Q37880734-BF482091-0A18-4D5B-97EC-8C257CDED499Q37881948-00519873-2CA5-49C8-8AF9-89C5A5C563A0Q38086474-8DE2F20F-E184-4C35-8340-3E3DB9D735A7Q38582520-73C04F60-3EFE-414D-8536-A212B9EC7E43Q40102845-76143E92-8FEE-4664-A773-6EC2517757E6
P2860
Alpha-synuclein in Lewy body disease and Alzheimer's disease.
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Alpha-synuclein in Lewy body disease and Alzheimer's disease.
@ast
Alpha-synuclein in Lewy body disease and Alzheimer's disease.
@en
type
label
Alpha-synuclein in Lewy body disease and Alzheimer's disease.
@ast
Alpha-synuclein in Lewy body disease and Alzheimer's disease.
@en
prefLabel
Alpha-synuclein in Lewy body disease and Alzheimer's disease.
@ast
Alpha-synuclein in Lewy body disease and Alzheimer's disease.
@en
P2860
P1433
P1476
Alpha-synuclein in Lewy body disease and Alzheimer's disease.
@en
P2093
Hashimoto M
P2860
P304
P356
10.1111/J.1750-3639.1999.TB00552.X
P577
1999-10-01T00:00:00Z